⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MLTX News
MoonLake Immunotherapeutics Class A Ordinary Shares
Did You Lose Money on MoonLake Immunotherapeutics (MLTX)? Levi & Korsinsky Urges Investors to Act Before December 15, 2025
accessnewswire.com
MLTX
SueWallSt Podcast Update: Levi & Korsinsky Details MLTX Class Action Claims
accessnewswire.com
MLTX
Contact Levi & Korsinsky by December 15, 2025 to Join Class Action Against MoonLake Immunotherapeutics (MLTX)
accessnewswire.com
MLTX
MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering
globenewswire.com
MLTX
MLTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that MoonLake Immunotherapeutics Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!
accessnewswire.com
MLTX
Pomerantz LLP Advises Shareholders of Class Action Involving MoonLake Immunotherapeutics – MLTX
accessnewswire.com
MLTX
MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab
globenewswire.com
MLTX
Securities Lawsuit Alert: MoonLake Immunotherapeutics (MLTX) - Contact Levi & Korsinsky Before December 15, 2025
accessnewswire.com
MLTX
MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman
accessnewswire.com
MLTX
Pomerantz LLP Alerts Shareholders to Investor Suit Filed Against MoonLake Immunotherapeutics – MLTX
accessnewswire.com
MLTX